(UroToday.com) For patients with muscle-invasive bladder cancer who are eligible for curative-intent treatment, cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is a standard of care with improved pathologic response and overall survival (OS) compared to RC alone. Consolidation with chemoradiotherapy (CRT) is an alternative to RC. Both of these consolidative approaches are associated with short and long-term toxicity and quality of life implications. Thus, there is interest in identifying patients in whom such consolidation could be omitted. In a plenary abstract presentation in the Rapid Abstract Session: Urothelial Carcinoma and Rare Tumors session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Geynisman presented results of a phase II, multi-institutional clinical trial (NCT02710734) to evaluate a risk-adapted approach to the treatment of muscle-invasive bladder cancer (MIBC).